

Special Issue

Research Progress of New Tuberculosis Vaccines and Vaccine Design

Message from the Guest Editors

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis* infection, and still a global public health problem. Mtb infection can arouse host innate and adaptive immune responses when entering the body. Innate immunity has an important role against Mtb infection. Airway epithelial cells, macrophages, neutrophils, dendritic cells (DCs), natural killer cells (NK), and mast cells, among others, are the major components of innate immunity. (1) Novel discovery of candidate protective antigens of *M. tuberculosis*; (2) The mechanism of the interaction between *M. tuberculosis* and the host; (3) The screening, identification, and validation of immunodominant epitopes of *M. tuberculosis* *in silico*, *vivo*, or *vitro*; (4) The construction and validation of multi-epitope vaccines for TB prevention; (5) New bioinformatics or immunoinformatic tools for TB vaccine development; (6) The trained immunity induced by the BCG vaccine and its potential roles on COVID-19 prevention; (7) The development of animal models used in TB vaccine evaluation.

Guest Editors

Dr. Wenping Gong

Institute of Tuberculosis, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing 100091, China

Dr. Ashok Aspatwar

Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland

Deadline for manuscript submissions

closed (31 May 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/159839

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).